Sentence examples for mouse prostate mice from inspiring English sources

For these experiments, we utilized female TRAMP (transgenic adenocarcinoma of the mouse prostate) mice transgenic for SV40 Tag 24.

TRAMP (transgenic adenocarcinoma mouse prostate) mice were randomly divided into two groups: normal diet group and HFD group.

Interestingly, it has been shown that TRAMP (transgenic adenocarcinoma of the mouse prostate) mice deficient in XIAP tend to have a more aggressive disease [ 26].

Further, Moore et al (2008) performed a study of tumour development and progression in TRAMP (transgenic adenocarcinoma of the mouse prostate) mice with wild-type PSCA and heterozygous and homozygous knockout for PSCA.

In accordance with this knowledge, decrease in ALDH1A2 in PC was associated with poor prognosis (Kim et al, 2005), and the reduction of both ALDH1A1 and ALDH1A2 was reported in the prostate of TRAMP (transgenic adenocarcinoma mouse prostate) mice in comparison with age-matched non-transgenic mice (Touma et al, 2009).

AhR knockout TRAMP (transgenic adenocarcinoma of the mouse prostate) mice develop tumors with increased severity and frequency compared with AhR-expressing counterparts, and treatment of TRAMP mice with the AhR ligand 6-methyl-1,3,8-trichlorodibenzofuran 6-methyl-1,3,8-trichlorodibenzofuran 6-methyl-1,3,8-trichlorodibenzofuran 6-methyl-1,3,8-trichlorodibenzofuran

A targeted approach using the TRAMP (transgenic adenocarcinoma of the mouse prostate) mouse model found a general increase in the expression of ECM-modifying proteases, such as MMPs and cysteine proteases, during tumor progression [ 42].

Concerning metastatic progression, activation of the Akt pathway has been shown to correlate with the chemotactic motility of prostate cancer cells in vitro (Jeong et al, 2012) and prostate tumour progression to metastasis in the transgenic adenocarcinoma mouse prostate mouse model (Sakamoto et al, 2010).

We used animals designed to develop this disease, Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mice, to investigate the potential role of AHR signaling in prostate cancer development.

Transgenic adenocarcinoma of the mouse prostate.

In the present study, we found that the expression of Nrf2 was suppressed in prostate tumor of the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) mice.